




Nicoumalone Tablets - Ip 1 Mg, Ip 2 Mg, Ip 3 Mg, Ip 4 Mg | Anticoagulant Medication For Blood Clot Prevention, Stroke & Heart Attack Risk Reduction
Price: 185.00 INR / Box
Get Latest Price
Minimum Order Quantity :
1000 Box
Brand Name :
Nicotrom
In Stock
Product Specifications
| Indication | Deep vein thrombosis, pulmonary embolism, and prevention of stroke in atrial fibrillation |
| Origin of Medicine | Allopathic |
| Dosage Form | Oral tablet |
| Pacakaging (Quantity Per Box) | 100 tablets |
| Salt Composition | Nicoumalone |
| Drug Type | Other, Generic |
| Ingredients | Nicoumalone |
| Physical Form | Tablets |
| Function | Other, Anticoagulant |
| Recommended For | Treating and preventing blood clots |
| Dosage | As directed by the physician |
| Dosage Guidelines | Take after food or as advised by a healthcare professional |
| Suitable For | Adults |
| Quantity | 10x10 tablets per box |
| Storage Instructions | Store in a cool, dry place; protect from light |
Product Overview
Key Features
Nicoumalone IP 2 Mg
Nicoumalone IP 3 Mg
Nicoumalone IP 4 Mg
Company Details
This is to introduce ourselves as a professionally managed fast growing Pharmaceutical Company having more than Five Years of Manufacturing and Marketing experience. We are based at Mumbai in the State of Maharashtra. The Company has been accredited with ISO-9001:2008 and manufactures pharmaceutical formulations as per the guidelines of WHO. It is a (GMP Certified) Unit with total quality management and In-house Testing Laboratory. Our success is the result of focusing on our clients top priorities such as quality products, on-time delivery, competitive rates and unparalleled responsiveness. Johnlee manufactures more than 400 plus Pharmaceutical Formulation Products in the form of Tablets, Capsules, Dry syrup, Liquid Orals and Sustained Release Preparations. It is the Company constant and Company will also increasingly focus in high growth potential segments like Vaccines and Biogenetics. These new areas will add significant depth to the existing product pipeline. The proteasome has been validated as an important clinical target in cancer, and Johnlee Pharmaceuticals Pvt. Ltd. is developing next-generation proteasome inhibitors with a high degree of selectivity, with the goal of increasing therapeutic efficacy and reducing side effects.
Business Type
Exporter, Manufacturer, Supplier
Employee Count
20
Establishment
2005
Working Days
Monday To Saturday
GST NO
27AGKPJ8183H1ZY
Payment Mode
Cash Advance (CA)
Related Products
More Products From This Seller
Seller Details
GST - 27AGKPJ8183H1ZY
Mumbai, Maharashtra
Director
Mr Vikram K Jain
Members since
12 Years
Address
Office No.22 to 25, 2nd Floor, 72/78, Chapsey Building, Ladwadi, Shamaldas Gandhi Marg, Princess Street, Mumbai, Maharashtra, 400002, India
nicoumalone in Mumbai
Report incorrect details
















